Food and Drug Administration
-
Inside FDA's New IT Acquisition Strategy
The agency wants to create shared solutions for the enterprise and centralize the IT infrastructure as part of a 10-year plan.
5m read -
Federal Tech Leads Reflect on What Makes Great CX
Following mandates to improve the customer experience, officials are embracing new workforce development approaches.
3m read -
FDA, VA are Moving Away from Paper-Based Processes
FDA and VA received FedHealthIT awards for their efforts to collect, store and analyze data to improve patient care.
5m read -
FDA CIO Talks New 'Enterprise Modernization Action Plan'
Vid Desai discusses FDA's next stage of IT transformation.
30m listen -
FDA CIO Leads New Digital Transformation Office
Newly confirmed CIO Vid Desai discusses how his role has evolved following the creation of FDA's Digital Transformation Office.
21m listen -
How AI, Data Are Boosting FDA's Regulatory Processes
A Presidential Innovation Fellow is helping the agency improve workflows and ultimately ensure safety of the drugs and treatments it regulates.
36m listen -
Securing Medical Devices and the Software Supply Chain
FDA is tackling security measures for the health technologies it regulates.
25m listen -
FDA's Tech Transformation Hinges on Data
CTO Vid Desai brings private sector successes to meeting agency missions.
25m listen -
Inside FDA's New Data Modernization Plan
The Food and Drug Administration today released its Data Modernization Action Plan (DMAP), emphasizing scalability of data modernization through a three-pronged actionable framework around data use cases, practices and talent.
7m read -
FDA Advances Digital Health Innovation With New Effort
With technology changing by the second, the agency's new center of excellence aims to keep medical software and devices safe for patients.
20m listen -
Supporting FDA Drug Reviews With Data Insights
The agency is looking to digital tools and automation to streamline regulatory decisions in health.
17m listen -
FDA Moves to 'Marathon Strategy' for COVID-19 Vaccine
The Food and Drug Administration is taking on a “marathon strategy” in place of its originally adopted sprint mentality for the review, authorization and approval of a novel coronavirus vaccine, according to the agency’s Center for Biologics Evaluation and Research (CBER) Director Peter Marks.
7m read
